A Phase I Study of ABT-510 in Combination With Bevacizumab in Advanced Solid Tumors
A Phase I Study of ABT-510 in Combination With Bevacizumab in Advanced Solid Tumors
The primary objective of this study is to determine the recommended Phase II dose for the
 combination of ABT-510 plus bevacizumab in patients with advanced solid tumors and to
 evaluate dose limiting toxicities and non-dose limiting toxicities of this combination. The
 secondary objectives are to collect preliminary data on the effect of the combination of
 ABT-510 plus bevacizumab versus each agent individually on dermal wound angiogenesis in a
 skin biopsy and to collect preliminary data on the clinical activity of this combination
 (tumor response rate, progression-free survival, rate of stable disease > 6 months).
ABT-510: In the early 1990s, thrombospondin (TSP-1) was first recognized as an endogenously
 produced inhibitor of angiogenesis. Since then, thrombospondin has been shown to inhibit
 neovascularization and tumorigenesis in numerous mouse models. Its anti- angiogenesis
 properties have been localized to its N-terminal region. Although smaller fragments of this
 region retain some of thrombospondin's anti-angiogenesis properties, researchers have
 discovered that specific amino acid substitutions can greatly enhance these properties. From
 these efforts, ABT-510, a nine-amino acid synthetic peptide has emerged as a novel
 anti-angiogenesis agent. The peptide is soluble and stable in water and is administered
 parenterally as an acetate salt in 5% dextrose solution for clinical use.

 ABT-510 has been evaluated in three Phase I studies: one single-dose study in healthy
 volunteers and two studies in cancer patients. Doses ranging from 10 mg to 260 mg have been
 evaluated as IV infusions (30-minute), subcutaneous bolus injections, or 24-hour subcutaneous
 infusions. Overall, ABT-510 has been well tolerated. A preliminary review of the 103 case
 report forms collected to date identified a total of 1306 adverse events. Ninety-one percent
 (1195/1306) of these events were considered to be mild or moderate in nature. Eighty-one
 percent (1052/1306) of these events were reported as not related to or probably not related
 to ABT-510. The most common adverse events, occurring in >10% of the patients, include
 injection site reaction, asthenia, abdominal pain, nausea, anorexia, pain, headache,
 vomiting, diarrhea, dyspnea, constipation, cough increased, back pain, peripheral edema,
 dizziness, insomnia, anemia, fever, sweating, chest pain, and rash.

 Bevacizumab (Avastin) is a recombinant, humanized, monoclonal antibody directed against
 vascular endothelial growth factor (VEGF). This antibody blocks binding of the ligand VEGF
 with its receptor. VEGF is known to play a pivotal role in tumor angiogenesis and is a
 significant mitogenic stimulus for arterial, venous, and lymphatic endothelial cells. It can
 induce vascular permeability essential for extracellular remodeling and can serve as an
 endothelial cell survival factor. Phase III studies in 1st line colorectal cancer, 2nd line
 colorectal cancer, 1st line breast cancer, and 1st line non-small cell lung cancer have all
 demonstrated clinical benefit in terms of overall survival, progression free survival, and
 tumor response [Refs.. HH NEJM, A Sandler ASCO2005, L Miller ASCO 2005]. Efficacy has also
 been noted in phase II studies of renal cell, ovarian, glioma, and other tumor types. Side
 effects of bevacizumab include approximately 10-20% rate of hypertension requiring
 anti-hypertensives, uncommon aterial thromboembolilc events (myocardial infarction, unstable
 angina, cerebrovascular events, transient ischemic attacks, etc) with background rates
 increased from approximately 1-2% to 2-4%, and an approximately 1-2% risk of GI perforation.

 Aside from this pivotal phase III colorectal cancer study, the dose of bevacizumab used for
 all other clinical trials has been 10mg/kg biweekly. A dose of bevacizumab at 10 mg/kg will
 be used in this study because it is consistent with the dosing used in most ongoing and
 planned bevacizumab studies and it has been shown, when compared to lower doses, to have
 comparable or improved activity.

 Based on available data, it is a reasonable hypothesis that the combination of ABT-510 and
 bevacizumab will be a safe and potentially efficacious anti-angiogenesis strategy for the
 treatment of adult solid tumors. This combination may have utility directly or may prove
 useful when subsequently combined with other anti-angiogenic agents or standard chemotherapy
 regimens. An important aspect of this proposed study will be the inclusion of a clinical
 dermal wound angiogenesis assay which will help quantify and characterize the anti-angiogenic
 contribution of each agent in this combination. Therefore, this study is meant to provide
 important safety information on this combination, but also insight into the additive
 mechanistic effects of two agents with different mechanisms of action.
Inclusion Criteria:

 -  Histologically or cytologically confirmed diagnosis of advanced solid tumor refractory
 to standard therapy or for whom there is no standard therapy.

 -  Patients must not have had radiation therapy, hormonal therapy, biologic therapy or
 chemotherapy for cancer within the 21 days prior to study Day 1. Patients must not
 have had major surgery within the 28 days prior to study Day 1 or minor surgical
 procedures within the 14 days prior to study Day 1.

 -  Age > 18 years.

 -  ECOG performance status of 0-1 (see Appendix A).

 -  Patients must have normal organ and marrow function as defined below:

 -  hemoglobin > 9.0g/dL; absolute neutrophil count > 1,500/μl; platelets >
 100,000/μl; total bilirubin < 1.5 X upper limit of normal (ULN),
 AST(SGOT)/ALT(SGPT) < 2.5 X ULN, < 5 X ULN if known hepatic metastases; Urine
 protein:creatinine ratio < 1.0; creatinine clearance > 50 mL/min/1.73 m2;
 PT/INR/PTT < 1.2X ULN

 -  The effect of the investigational drugs on the developing human fetus is not known,
 but these drugs are likely to be embryo- and feto- toxic. Women of child-bearing
 potential must agree to use adequate contraception (either surgical sterilization;
 approved hormonal contraceptives such as birth control pills, Depo-Provera, or Lupron
 Depot; barrier methods such as condom or diaphragm along with spermicide; or an IUD).
 Should a woman become pregnant or suspect she is pregnant while participating in this
 study, she should inform her treating physician and study PI immediately. Patients
 should be willing to use adequate contraception for three months following
 discontinuation of study drug.

 -  The patient is able to self-administer or has a caregiver who can reliably administer
 subcutaneous injections.

 -  Ability to understand and the willingness to sign a written informed consent document.

 Exclusion Criteria:

 -  Patients who have had radiation therapy, hormonal therapy, biologic therapy, or
 chemotherapy for cancer within the 21 days prior to Day 1 of the study. Patients with
 prostate cancer who are already receiving androgen deprivation therapy (ie. leuprolide
 or goserelin) for longer than 3 months may continue on this therapy during the study.

 -  Patients who have received any other investigational agents within the 28 days prior
 to Day 1 of the study.

 -  Patients with known brain metastases should be excluded from this clinical trial
 because of their poor prognosis, the uncertain risk of this regimen on tumor bleeding,
 and because these patients often develop progressive neurological dysfunction that
 would confound the evaluation of neurologic and other adverse events. Patients with
 primary malignancies known to metastasize to the brain (such as lung cancer, breast
 cancer, renal cell cancer, , sarcoma, carcinoma of unknown primary, melanoma, and head
 and neck cancers) or patients with symptoms of brain metastases should have a brain
 MRI within 28 days of enrollment to confirm the absence of CNS metastases. Contrast CT
 is acceptable for patients who are unable to undergo a brain MRI.

 -  Patients with poorly controlled or clinically significant atherosclerotic vascular
 disease including CHF NY Heart Class > 2 (see Appendix B); angina requiring nitrates;
 MI, CVA, TIA, angioplasty, cardiac or vascular stenting in the past 6 months; or
 ventricular arrhythmia requiring medication.

 -  History of intolerance of prior treatment with bevacizumab or ABT-510. Prior treatment
 with these agents is otherwise permitted.

 -  Poorly controlled hypertension (> 160/100). Initiation or adjustment of BP medication
 is permitted prior to study entry provided that patient has 3 consecutive BP readings
 less than 150/90 mmHg each separated by a minimum of 24 hours. These readings should
 be collected prior to first skin biopsy.

 -  History of thrombosis within 3 months prior to enrollment or current use of
 therapeutic anticoagulation. Prophylactic low-dose anticoagulation for indwelling
 catheters is permitted; PT/PTT must be within normal limits.

 -  Use of antiplatelet agents other than aspirin (< 325 mg/day) or standard dose NSAIDs.

 -  Presence of bleeding diathesis, coagulopathy, or major bleeding event such as an acute
 GI bleed requiring transfusion or invasive intervention or hemoptysis greater than 1
 tablespoon within 6 months prior to Day 1 of the study.

 -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
 infection, or psychiatric illness/social situations that would limit safety or
 compliance with study requirements. In addition, patients with non-healing wounds will
 not be eligible for this study.

 -  Pregnant women are excluded from this study because the investigational drugs have
 potential for teratogenic or abortifacient effects. Because there is an unknown but
 potential risk for adverse events in nursing infants secondary to treatment of the
 mother with these drugs, breastfeeding should be discontinued if the mother is treated
 on this study.

 -  Patients with squamous cell carcinoma of the lung.

 -  History of intra-abdominal fistula, gastrointestinal perforation or intr-abdominal
 abscess within 6 months prior to Day 1.